Revolutionizing Discovery of Aptamer Therapeutics

Characteristics

• Typically 15-40 nucleotides in length (5-15 KDa)
• Non-immunogenic
• Clinically validated
• Guardian’s fully stabilized aptamers
• Stable in serum (>120 hours)
• Stable in gastric acid and intestinal fluid (≥24 hours)

Amenable to chemical conjugation post synthesis (i.e. toxin, half life extension compounds)

• Site-specific conjugation using NHS-, thiol or Click chemistry
• Payload Delivery (Toxin, siRNA, etc)
• 1:1 stoichiometry of conjugation of targeting and payload moieties
• Per gram of drug there is more payload for ApDC than ADC
• Half Life extension
• PEGylated aptamer demonstrates 9-day human half-life
• Proprietary fatty acid conjugated aptamer >24-hour monkey half-life

Manufacturing

• CMC is a chemical synthesis process allowing for easy and rapid scalable manufacturing
• No cell line or cell bank involvement
• Enables a lower cost of goods for conjugates constructs and bispecifics